Flamel Technologies S.A. (AVDL) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Flamel Technologies S.A. (NASDAQ:AVDL) have been assigned an average rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $21.40.
A number of brokerages have recently issued reports on AVDL. Zacks Investment Research upgraded shares of Flamel Technologies from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Monday, July 17th. Ladenburg Thalmann Financial Services lifted their price objective on shares of Flamel Technologies from $27.00 to $30.00 in a research report on Thursday. Roth Capital set a $15.00 price objective on shares of Flamel Technologies and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Langenberg & Company reiterated a “buy” rating and issued a $30.00 price objective (up from $27.00) on shares of Flamel Technologies in a research report on Thursday.
In related news, Director Guillaume Cerutti sold 26,560 shares of Flamel Technologies stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $10.46, for a total transaction of $277,817.60. Following the completion of the sale, the director now owns 23,440 shares in the company, valued at approximately $245,182.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of Flamel Technologies stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $10.68, for a total value of $2,787,480.00. The disclosure for this sale can be found here. 5.07% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of AVDL. Russell Investments Group Ltd. purchased a new stake in Flamel Technologies in the 1st quarter valued at about $3,654,000. US Bancorp DE purchased a new stake in shares of Flamel Technologies during the 1st quarter worth about $121,000. Acadian Asset Management LLC grew its holdings in shares of Flamel Technologies by 9.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,672,207 shares of the company’s stock worth $18,444,000 after purchasing an additional 147,907 shares during the period. State of New Jersey Common Pension Fund D grew its holdings in shares of Flamel Technologies by 27.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 42,090 shares of the company’s stock worth $464,000 after purchasing an additional 9,175 shares during the period. Finally, Sei Investments Co. grew its holdings in shares of Flamel Technologies by 29.5% during the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after purchasing an additional 2,900 shares during the period. Institutional investors own 69.09% of the company’s stock.
Flamel Technologies (NASDAQ:AVDL) traded up 6.04% during mid-day trading on Thursday, reaching $8.96. 211,009 shares of the company’s stock traded hands. The stock has a market capitalization of $359.15 million, a PE ratio of 9.46 and a beta of 1.39. The stock has a 50-day moving average price of $9.19 and a 200-day moving average price of $9.87. Flamel Technologies has a 12-month low of $8.14 and a 12-month high of $14.38.
Flamel Technologies (NASDAQ:AVDL) last issued its earnings results on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.14. The firm had revenue of $46.30 million for the quarter, compared to analysts’ expectations of $45.17 million. Flamel Technologies had a net margin of 21.13% and a return on equity of 29.84%. The business’s revenue for the quarter was up 19.0% on a year-over-year basis. Equities research analysts expect that Flamel Technologies will post $1.11 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/07/flamel-technologies-s-a-avdl-given-consensus-recommendation-of-buy-by-brokerages.html.
About Flamel Technologies
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.